Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Neoprobe

This article was originally published in The Gray Sheet

Executive Summary

Reduces workforce by 20% and intends to reduce operating expenditures in 1998 by approximately 30% as part of a "strategic assessment and restructuring" announced Feb. 18. The Dublin, Ohio firm plans to refocus resources on its three key business goals: commercializing its RIGScan CR49 system for surgical detection of metastatic colorectal cancer; maximizing instrument sales for gamma guided surgery applications and developing activated cellular therapy products for cancer and viral diseases. The company, which anticipates an operating loss of about $12 mil. in fiscal 1998, hopes "to move the company toward profitability" in fiscal 1999. As part of the restructuring, David Bupp, president and chief operating officer, gains the title of CEO from John Ridihalgh, who remains chairman...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel